United States & Boehringer Ingelheim
8 shared events · Importance 3 · Last updated Sep 22, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
United States: The US is part of North America, which held the largest market share in 2025, supported by strong regulatory frameworks and advanced manufacturing.
Boehringer Ingelheim: Boehringer Ingelheim is a key player in the antibody therapeutics market, benefiting from the projected market growth.
Jul 28, 2026 · 6 articles
Regulatory
United States: Cited as a key competitor attracting far more pharmaceutical investment, with healthcare spending at about 2% of GDP versus Europe's 1%. Its more aggressive policies are said to be drawing capital and launches away from Europe.
Boehringer Ingelheim: One of the nine signatories of the open letter urging EU action on medicine spending, trials and IP protection. Its participation signals shared industry concern over European competitiveness.
Sep 22, 2026 · 6 articles
Tech
United States: The study focuses on U.S. populations, particularly the Southern Appalachian region, and may influence national screening guidelines and public health policy.
Boehringer Ingelheim: Boehringer Ingelheim's past deal with Hanmi Pharm for olmutinib is mentioned as a historical example of EGFR therapy development challenges.
Sep 17, 2026 · 6 articles
Tech
United States: The study population is U.S.-based, and findings may influence public health recommendations.
Boehringer Ingelheim: Andrew T. Chan served as a consultant; no direct impact.
Aug 17, 2026 · 20 articles
Tech
United States: Obesity epidemic in children drives demand for treatments; policy implications.
Boehringer Ingelheim: Orandi served on advisory board; not directly involved.
Sep 04, 2026 · 7 articles
Business
United States: Mentioned in the context of U.S. government responses to Chinese innovation, but not directly involved in the transaction.
Boehringer Ingelheim: Mentioned as a previous partner of Grand Pharmaceutical Group, highlighting the platform's track record but not directly affected by this deal.
Jul 20, 2026 · 11 articles
International
Boehringer Ingelheim: Boehringer Ingelheim managers are traveling with Friedrich Merz, indicating a focus on deepening cooperation in the pharmaceuticals sector with India.
Jan 11, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States and Boehringer Ingelheim interact across events, view sentiment trends, and discover connected entities.
Open Dashboard